Ad-Rts-Hil-12
Anaplastic Oligoastrocytoma
Alaunos TherapeuticsPhase 1Dormant
C
36/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 21/ 100
- Competitive Position
- 95/ 100
Competitive context
4 Active assets in the Anaplastic Oligoastrocytoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
CARMUSTINE Shandong Lanjin Pharmaceuticals Co.,Ltd | Phase 3 | B |
Α-Ifn Sun Yat-sen University | Phase 3 | B |
Β-Elemene Sun Yat-sen University | Phase 3 | B |
Dendritic Cells Pulsed With Tumor Lysate Jonsson Comprehensive Cancer Center | Phase 2 | B |
Tandutinib National Cancer Institute (NCI) | Phase 2 | B |
View all 37 →
Same molecule, other indications
Ad-Rts-Hil-12 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →